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ABSTRACT 
 
Pulsatile drug delivery systems have been a major field of research recently. It is the most interesting time-specific 
and site-specific system. This system is designed for chronopharmacotherapy which is based on circadian rhythm. 
This means these systems will deliver drug at the time when disease displays it's most morbid and mortal state 
within a circadian cycle. The use of these systems has been investigated on diseases like asthma, arthritis, ulcers, 
cardiovascular diseases, hypercholesterolemia, cancer etc. Various capsular, osmotic, single and multiple unit 
systems that are modulated by soluble or erodible polymer coatings, rupturable membranes are discussed in the 
article below. 
Keywords: Pulsatile, deliver, drug . 
Introduction 
 
The oral controlled release drug delivery systems are 
way much better than the conventional immediate 
release delivery preparations. With the help of these 
advanced systems, a drug can be delivered at a 
controlled and pre- determined rate, therefore, 
producing their therapeutic effect for a much longer 
period. Also, for some therapies, a pulsatile drug 
release pattern is used, in which the drug is released 
into the body after a well- defined lag time. [1]Pulsatile 
Drug Delivery System (PDDS) is a time- specific and 
site-specific drug delivery system, thereby it provides 
special and temporal delivery and increase patient 
compliance also. This system can be of great use for 
the drugs which do not require a constant drug release 
i.e. do not desire a Zero- order release.  PDDS can be 
defined as the rapid and transient release of certain 
number of molecules within a short–time immediately 
after a pre–determined off-release period, i.e. lag time. 
Lag time is defined as the time between the placement 
of dosage form into an aqueous environment and the 
time at which the active ingredient begins to get 
released from the dosage from. [2]  
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 ‘Chrono pharmaceutics’ is a word made after 
compiling two words, Chronobiology and 
Pharmaceutics. Chronobiology is the study of 
biological rhythms and their mechanisms. There are 3 
types of mechanical rhythms in our body: - 
• Circadian: This word comes from Latin word 
‗circa‘ means about and ‗dies‘ means day.  
• Ultradian: Oscillations of shorter duration are 
termed as ultradian (more than 1 cycle 24 hrs) [5] 
• Infradian: Oscillations that are longer than 24 hrs 
(less than one cycle per day) [3] 
It is well- documented that majority of the body 
functions exhibit circadian rhythms e.g. heart rate, 
stroke volume, blood pressure, blood flow, body 
temperature, gastric pH etc. Moreover, in a 
number of organs their functions vary with the 
time of the day. [4] 
Diseases requiring Pulsatile Drug Delivery 
Many of our body functions like metabolism, sleep 
patterns, behaviour, physiology and hormone 
production are regulated by circadian rhythm. Capillary 
resistance and vascular reactivity are higher in the 
morning and decrease in the day later on. Circadian 
changes are observed in normal lung functioning, 
which is very low in early morning hours. Also, Blood 
pressure is found to be high in the morning and low 
during night. Rheumatoid arthritis patients suffer more 
pain in the morning period while osteo- arthritis 
patients feel more pain in the night time. In all such 
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diseases, pulsatile drug delivery can be immensely beneficial. [6-7] 
Table  1: shows some of the diseases [8] 
Disease  Chronological behaviour  Drugs used  
Peptic Ulcer  Acid recreation is high in after - 
noon and at night 
H2 blockers  
Asthma  Precipitation of attacks during 
night or at early morning hours  
B
2
 agonist, Antihistaminics  
Cardiovascular diseases  BP is at its lowest during the sleep 
cycle and arises steeply during 
early morning awakening period   
Nitro-glycerine, calcium channel 
blocker, ACE inhibitors etc.  
Arthritis  Pain in the morning and more pain 
at night.  
Glucocorticoids.  
Diabetes Mellitus  Increase in the blood sugar level 
after meal  
Sulphonyl urea, Insulin.  
Attention deficit syndrome  Increase in DOPA level in 
afternoon.  
Methylphenidate  
Hypercholesterolemia Cholesterol synthesis is generally 
high during night than day time  
HMC CoA reductase inhibitors  
The shift from conventional sustained release to 
modern pulsatile drug delivery can be credited to 
the following reasons 
First Pass Metabolism 
A few drugs, like beta blockers and salicylic amide, 
undergo extensive first pass metabolism and require 
fast drug input to saturate metabolizing enzymes in 
order to minimize pre-systemic metabolism. Thus, a 
constant / sustained oral delivery method would result 
in reduced oral bio- availability. 
Biological tolerance: Continuous release drug plasma 
profiles are often accompanied by a decline in the 
pharmacotherapeutic effect of the drug, e.g. biological 
tolerance of transdermal nitro-glycerine. 
Special chrono pharmacologicalneeds:  Circadian 
rhythms in certain physiological functions are now well 
– known and well established. It has been recognized 
that a lot of symptoms and onset of disease occur at 
specific time periods of 24-hour day, e.g. asthma and 
angina pectoris attack we most frequent in morning 
hours.  
Local therapeutic needs:  For the treatment of local 
disorders such as inflammatory bowel disease, there is 
a need of delivery of compounds at the site of 
inflammation with no loss due to absorption in small 
intestine to minimize the side effects.  
Gastric irritation or drug instability in gastric fluid:  
For the compounds with gastric irritation or chemical 
instability in gastric fluid, the use of sustained release 
preparation may increase gastric irritation and chemical 
instability in gastric fluid. [8]  
Drug absorption differences in various gastro – 
intestinal segments 
Generally, the drug absorption is moderately slow in 
the stomach, rapid in the small intestine and sharply 
declining in the large intestine. So, the drugs targeted 
to the colon region could not be properly effective due 
to pre–absorption in earlier gastro- intestinal tract. [8-
9] 
Methodologies for PDDS  
Methodologies for PDDS can be briefly classified into 
4 classes,  
Time controlled Pulsatile Release  
Single Unit System  
Multi Particulate System  
Stimuli – induced  
Thermo – responsive pulsatile release  
Chemical stimuli induced Pulsatile systems  
External stimuli pulsatile release  
Pulsatile release systems for vaccines and hormone 
products [10]  
Time  controlled Pulsatile Release System  
 The time controlled systems can be classified as single 
unit (e.g. tablets and capsules) or multiple unit systems.  
Single unit Systems  
Capsular Systems  
A variety of single – unit PDDS have been developed. 
A general layout of such systems consists of an 
insoluble capsule body consisting of a drug and a plug. 
This plug is removed after a pre- determined lag time 
due to swelling, erosion or dissolution. 
Pulsincap system is a good example of such a system 
which is made up of such a system that is made up of a 
water – insoluble body filled with drug formulation. 
[11] The body has a closed and an open- end closed 
with a swellable hydrogel plug. This plug, when comes 
in contact of the dissolution medium or gastro – 
intestinal fluids, gets swollen up, and pushes itself out 
of the capsule after a time lag, which is followed by a 
spontaneous release of the drug. The time lag can be 
 
Asian Pac. J. Health Sci., 2018; 5(3):260-270                                            e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________  
Sharma et al                    ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2018; 5(3):260-270 
www.apjhs.com                                    262 
 
controlled by the manipulation of the dimensions and 
position of the plug. Inclusion of effervescent agents or 
disintegrants ensures a spontaneous release is case of 
water insoluble drugs. The plug material consists of 
insoluble but permeable and swellable polymers [12-
13] (e.g. polymethacrylates), erodible compressed 
polymers (Polyvinyl alcohol, polyethylene oxide), 
congealed melted polymers (saturated polyglycolated 
glycerides), controlled erodible polymer .(pectin). 
These formations are well tolerated in animals and 
healthy volunteers, and there are no reports of gastro – 
intestinal irritation. The problem of gastric residence 
time has been overcome by enteric coating the system 
to allow its dissolution only in the higher pH region of 
small intestine. 
Port Systems 
This system consists of gelatine capsule coated with a 
semi – permeable membrane (e.g. cellulose acetate) 
along with an insoluble plug (e.g. lipidic). It also 
contains an osmotically active agent along with the 
drug formulation [14]. In presence of an aqueous 
medium, the water diffuses across the semi- permeable 
membrane, leading to increased inner pressure that 
ejects the plug after predetermined time lag. The lag 
time can be controlled by the thickness of the semi 
permeable membrane. This system shows a good 
correlation b/w lag time of in- vitro and in- vivo 
experiments in human beings. [15].An osmotically 
driven capsular system was developed to deliver the 
drug in liquid form. In this system, the liquid drug is 
absorbed into highly porous particles. These particles 
release the drug through an orifice of semi – permeable 
capsule supported by an expanding osmotic layer after 
the dissolution of the barrier layer. [16] The wall of the 
capsule is made up of an elastic material and also 
possesses an orifice. Due to osmosis, there is an 
increase in the pressure inside the capsule, resulting in 
stretching of the wall. As the orifice in very minute, 
there is no flow of drug when the elastic wall relaxes. 
But as the wall stretches, the orifice also expands 
sufficiently enough for the release of the drug at a 
required rate. Styrene –butadiene is one of the 
suggested elastomers. [17-18] 
Delivery by a series of stops  
This system is described specifically for the 
implantable capsules. Here, the capsule consists of a 
drug along with a water- absorptive osmotic engine 
which are placed in different compartments separated 
by a movable partition. The pulsatile delivery is due to 
a series of stops along the inner wall of the capsule. 
These stops cause an obstruction in the movement of 
the partition but later on, due to the rise in osmotic 
pressure above a threshold level, these obstructions are 
overcome. The number and frequency of the pulses can 
be managed by changing number of stops and 
longitudinal placements in the capsule. Pulse intensity 
is controlled by the configuration of the partition. 
Porcine somatotropin was delivered by this system. 
[19]  
Delivery by solubility modulation 
A solubility modulator is present for pulsed delivery of 
a variety of drugs in these systems. The system was 
especially developed for the delivery of salbutamol 
sulphate [20]. The compositions consist of a drug 
(salbutamol sulphate) along with a modulating agent 
(sodium chloride). The amount of NaCl was less than 
that required to maintain saturation in a fluid entering 
the osmotic device. Pulsed delivery depends on the 
drug solubility. Salbutamol has solubility of 275mg/ml 
in water and 16 mg/ml in saturated solution of NaCl, 
while NaCl has solubility of 321 mg/ml in water and its 
saturation solubility is 320 mg/ml. These values show 
that the solubility of a drug is a function of the 
modulator's concentration, while the modulator's 
solubility is largely independent of drug concentration. 
The modulating agent can be a solid organic acid, 
inorganic acid or organic salt.  
Delivery by reservoir systems with erodible or 
soluble barrier coatings 
PDDS are mostly reservoir devices which are coated 
with a barrier layer. After a specific lag period, barrier 
erodes, or dissolves and subsequent and rapid release 
of drug takes place. The thickness of the coating layer 
is a factor on which the time lag depends. [21]  
The Time Clock System  
Consists of a solid dosage form coated with lipid 
barrier which contain carnauba wax and Bees wax 
along with surfactants, like, poly oxyethylene sorbitan 
monooleate. [22] [23] In an aqueous environment, this 
coat erodes or emulsifies with time proportional to the 
thickness of the film and the core dispersion takes 
place. There is no need of any special equipment and 
the manufacture is easy. However, a premature drug 
release is often when the penetrating water dissolves 
the drug.  
The Chronotropic System 
Consists of a drug containing core coated by 
hydrophilic swellable hydro propyl methyl cellulose 
(HPMC), which is mainly responsible for a lag phase 
in the drug release. The thickness and the viscosity 
grades of the HPMC used in coating control the time 
lag. Both tablet and capsule formulations are favoured 
by this system. [24-25] 
Multi – particulate Systems  
Multi particulate drug delivery systems are chiefly oral 
dosage forms consisting of a number of small discrete 
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units, which contain the active substance as 
independent sub – units. 
Advantages over single – unit systems 
They have small size and there is no risk of dose 
dumping.  
There is less inter and intra subject variability in 
gastro–intestinal transit time. 
There are less adverse effects and also improved 
tolerability.There is flexibility in design and stability 
also  
Disadvantages 
Lack of manufacturing reproducibility 
High production cost  
Multiple formulation steps  
Need of advanced technologies. [10] 
Different types of multi – particulates systems are 
described below 
Pulsatile system based on rupturable coating  
These are multiparticulate systems in which the drug is 
coated on non- partial sugar seeds followed by a 
swellable layer and an insoluble top layer coating 
(Ueda et at 1994). The swelling agents used include 
super disintegrants like sodium carboxymethyl 
cellulose, sodium starch glycollate and polymers like 
polyvinyl acetate, polyacrylic acid, polyethylene glycol 
etc. Effervescent system comprising a mixture of 
tartaric acid, citric acid and sodium bicarbonate may 
also be used alternatively. Upon entrance or ingress of 
water, the expansion of swellable layer takes place 
leading to rupture of film with the subsequent rapid 
drug release. The environmental factors like pH and 
drug solubility do not affect the release of drug at all. 
Variation in coating thickness or addition of high 
amounts of lipophilic plasticizer in the outermost layer 
can lead to variation in the lag time. With increase in 
concentration of osmotic agent, a rapid release after the 
lag phase can be achieved. [26] [27] 
Time controlled expulsion system  
This system is based on a combination of osmotic and 
swelling factors. The core consists of the drug, a low 
bulk density solid and/or liquid lipid material (e.g. 
mineral oil) and a disintegrant also. The core further 
contains a coating of cellulose acetate. When immersed 
in an aqueous medium, the water penetrates the core 
and displaces the lipid material [28]. Subsequently, an 
increase in internal pressure takes place resulting in 
rupturing of the coating material. This system is also 
known as Osmotic based rupturable coating system. 
Another system is based on a capsule or tablet 
composed of a large no. of pellets with different release 
pattern. [29] The core consists of the therapeutic drug 
and a water soluble osmotic agent in each pellet. The 
core is enclosed by water – permeable, water insoluble 
polymer film. The polymer film is incorporated with a 
hydrophobic, water insoluble agent that alters the 
permeability (e.g. wax, fatty acid or a salt of fatty 
acid). The film coating of each population differs from 
another pellet coating due to water influx and drug 
efflux. The rate of drug diffusion is regulated by the 
swelling of pellets due to the dissolution of osmotic 
agent. A single dosage form provides a series of pulses 
as each pellet population releases its drug content. This 
system was used for the delivery of anti- hypertensive 
drug diltiazem.Also, some osmotically active agents 
are used that do not undergo swelling. These pellet 
cores consist of drug along with sodium chloride 
coated with semi-permeable cellulose acetate polymer. 
The coat is selectively permeable to water and is 
impermeable to the drug. The presence of sodium 
hydroxide produces fast release of drug while its 
absence gives sustained release after the lag time.  [30] 
Pulsatile Delivery by change in Membrane 
Permeability  
The presence of different counter–ions in the medium 
can influence the permeability and water uptake of 
acrylic polymers with quaternary ammonium groups 
[31]. Several delivery systems based on this ion 
exchange have been developed. Eudragit is a polymer 
of choice for this purpose [32]. It contains positively 
polarized quaternary ammonium group in the polymer 
side chain, that are always accompanied by negative 
hydrochloride counter ions. As the ammonium group is 
hydrophilic, it facilitates the interaction of polymer 
with water and thereby changes its permeability and 
allows the water to permeate the active core in a 
controlled manner. This property is essential to achieve 
precisely defined lag time. Theophylline, was used as 
model drug with sodium acetate used to prepare the 
cores. These pellets were coated using Eudragit (10% 
to 40% weight gain) in 4 different layer thicknesses. A 
correlation b/w film thickness and lag time was 
observed. The permeability of the eudragit film was 
affected dramatically even with a small amount of 
sodium acetate in the pellet core. After the lag time, the 
interaction between acetate and polymer increases the 
permeability of the coating such that the entire dose is 
liberated within a few minutes. [31] The lag increases 
with increasing thickness of the coat, but the release of 
drug was not affected by this thickness and depended 
on the amount of salt present in the system.  
Sigmoidal Release System  
This system comprises of pellet core containing drug 
and succinic acid coated with ammonia – methacrylate 
copolymer. [33] The permeability of the film is 
enhanced by the drug inside and the acid solution. The 
water in the medium dissolves Succinic acid. In place 
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of succinic acid, acetic acid, glutaric acid, tartaric acid, 
malic acid and citric acid is also used. This system was 
used to design an acid containing core.(Narisowa et at. 
1994,1996) [34] [35] [36] 
Low Density floating multi – particulate pulsatile 
systems  
All the systems mentioned above have longer residence 
time in gastro – intestinal tract and may result in ‗in 
vivo‘ variability and bio- availability problems. On the 
other hand, low density floating multi particulate 
systems reside only in stomach and are independent of 
variability of pH, local environment or gastric 
emptying rate. These are specifically advantageous for 
drugs either absorbed by stomach or those requiring 
local delivery in stomach. [37] 
Stimuli – induced pulsatile systems  
 In these systems, stimulation by any biological factor 
like temperature or any other chemical stimuli leads to 
release of the drug [38]. Further classification is as 
follows 
Thermo – responsive Pulsatile Release  
Thermo – responsive hydrogel systems have been 
developed for pulsatile release. In these systems, the 
polymer swells or deswells in response to temperature 
which modulate drug release in swollen state (Survase 
et at 2007) [39] 
Chemical stimuli induced Pulsatile system 
Glucose – responsive Insulin release devices  
In the case of Diabetes mellitus, a rhythmic increase in 
the levels of glucose is noticed in the body, requiring 
an injection of insulin at proper time. Several systems 
which are able to respond to changes in glucose 
concentration have been developed. One such system 
includes pH sensitive Hydrogel containing glucose 
oxidase immobilized in the hydrogel. Upon the 
increment of glucose concentration in the blood, 
Glucose is converted into Gluconic Acid by Glucose 
oxidase which changes the pH of the system. This 
change in the pH induces swelling of polymer which 
results in insulin release. Insulin by its action, reduces 
blood glucose level and consequently gluconic acid 
level is also decreased and the system turns to 
deswelling mode thereby decreasing the insulin release. 
Examples of pH sensitive polymers include N, N – 
dimethyl aminoethyl methacrylate, chitosan, polyol etc. 
[40-42] 
Inflammation induced pulsatile release  
Inflammation is a natural phenomenon that occurs on 
receiving any physical or chemical stress such as 
injury, fracture etc. at the injured site. These 
inflammation responsive cells produce hydroxyl 
radicals. It is possible to treat patients with 
inflammatory diseases like rheumatoid arthritis, using 
anti – inflammatory drug incorporated HA gels or 
Hyaluronic Acid gels as new implantable drug delivery 
system. [42-43] 
Drug release form intelligent gels responding to 
antibody concentration  
Numerous kinds of bioactive compounds exist in the 
body. Recently, novel gels were developed which 
responded to the change in concentration of bioactive 
compounds to alter their swelling/ deswelling 
characteristics. The antigen – antibody complex 
formation was given special attention as cross – linking 
units in the gel, since such interaction is very specific. 
Utilizing the difference between polymerized 
antibodies and naturally derived antibodies‘ association 
constants towards specific antigens, reversible gel 
swelling/ deswelling and drug permeation changes 
occurs. [39] [42] 
pH sensitive Drug Delivery System  
This system comprises of 2 components – fast release 
type and pulsed release type. The pulsed release type 
releases drug in response to change in pH. Its main 
advantage is the fact that there exists different pH 
environment at different parts of the GIT. Drug release 
at specific location can be obtained by selecting pH 
dependent polymers like acetate phthalate, poly 
acrylates and sodium carboxy methyl cellulose. The 
polymers are used as enteric coating materials so as to 
provide release of drug in the small intestine. [39]  
External Stimuli Pulsatile release  
These systems are not self – regulating, but instead 
require externally generated environmental changes to 
initiate drug delivery. These can include magnetic 
fields, ultrasound, temperature, light etc.  
Magnetic Field  
Use of an oscillating magnetic field to modulate the 
rates of drug delivery from a polymer matrix was one 
of the first methodologies investigated to achieve an 
externally controlled drug delivery system. [44] 
 Magnetic steel beads were embedded in an ethylene 
and vinyl acetate (EVAC) copolymer matrix that was 
loaded with bovine serum albumin as a model drug. 
[45]  
During exposure to magnetic field, the beads start 
oscillating within the matrix, therefore creating 
compressive and tensile forces. These forces act as a 
pump to push an increased amount of the drug 
molecule out of the matrix. The co-polymers having 
higher Young‘s modulus were more resistant to 
induced motion of steel beads, thereby, magnetic field 
has less effect on rate of drug release from these 
materials. [46] 
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Also, different Formulations were developed for in-
vitro magnetically triggered delivery of insulin based 
on alginate spheres. [47] 
A treatment method that involves the administration of 
a magnetic material composition, which contains 
single-domain magnetic particles attached to a target-
specific ligand, to a patient and the application of an 
alternating magnetic field to inductively heat the 
magnetic material composition, which cause the 
triggered release of therapeutic agents at the target 
tumour or cancer cells, also exists. [48]     
Ultrasound  
Ultrasound is used for improving drug permeability 
across biological barriers such as skin, lungs, intestinal 
wall and blood vessels. Many reports describe the 
effect of ultrasound on controlled drug delivery. [49-
55] Kost et.at described an ultrasound – enhanced 
polymer degradation system. 
As degradation of biodegradable matrix was enhanced 
by ultrasonic exposure, the rate of drug release also 
increased. Therefore, pulsed drug delivery was 
achieved by the on- off application of ultrasound. [56] 
Supersaxo et. at also reported macromolecular drug 
release from biodegradable poly microspheres. A 
sustained release can be maintained up to a several 
months. Authors speculated that ultrasonic exposure 
results in the enhancement of water permeability within 
microspheres of the polymer matrix, inducing drug 
dissolution into the releasing media. [57] There was an 
increase up to 27 times in the release of 5 Fluorouracil 
from an ethylene and vinyl acetate matrix using 
Ultrasound. an increase in the strength of ultrasound 
resulted in a proportional increase of 5 fluorouracil. 
[58]Increase in the rate of p-nitroaniline from a 
polyanhydide matrix during ultrasonic irradiation is 
reported [59]. It was noted that there was an increase in 
drug delivery was greater than the increase in matrix 
erosion when the ultrasound triggering was active. 
therefore, it was hypothesised that acoustic cavitation 
by ultrasonic irradiation was responsible for the 
modulated delivery of p-nitroaniline. [50] 
Temperature  
Temperature is most widely utilized stimulus for a 
variety of pulsatile drug delivery systems. Its use has 
been justified by the fact that the temperature of human 
body often deviates from physiological temp i.e. 37
o
c. 
Bae. Y.H. et. al. developed Indomethacin pulsatile drug 
delivery system in temperature range between 20-30 
degree Celsius by using reversible swelling properties 
of co polymer of N-isopropylacrylamide and butyryl 
acrylamide. [60] This deviation can be used as a 
stimulus that activates the release of the therapeutic 
agents from various temperature – responsive drug 
delivery systems for disease accompanying fever. 
Thermal stimuli – regulated pulsed drug release is 
established through the design of drug delivery devices 
such as hydrogels and micelles. [61] 
Thermo-responsive hydrogel systems comprise of 
hydrogels that undergo reversible volume changes in 
response to changes in the temperature. These 
thermally-responsive hydrogels and membranes have 
been evaluated extensively for the pulsatile drug 
delivery of the drugs.[62].For example, thermally-
responsive poly(N-isopropyl acryl amide)(PIPAAm), 
which show swelling at temperatures below 32 degrees 
and shrinking above this temperature. Drug release 
from the PIPAAm hydrogels at temperature below 
32degrees was governed by Diffusion but above this 
temperature the drug release was completely stopped 
because of the 'skin layer ' formation on the gel surface 
(on-off drug release regulation).[63-66] PIPAAm 
hydrogels showed rapid deswelling kinetics without 
any formation of skin layer on surface .This is possibly 
due to rapid dehydration of graft chains formed by 
hydrophobic aggregation on the three-dimensional 
cross-linked chains. [67-68] Also a similar rapid 
deswelling phase was achieved by incorporation of 
poly(ethylene glycol) graft chains in PIPAAm cross 
linked hydrogels. [69] 
Yuk et al. designed temperature -sensitive drug 
delivery systems using a mixture of poly (ethylene 
oxide)-poly (propylene oxide)-poly (ethylene oxide) 
triblock copolymer (F-68) and poly vinyl 
alcohol(PVA) [70]. The ratio of F-68/PVA could be 
changed to alter the swelling transition of polymer 
complex gel. The pulsatile release of acetaminophen in 
response to pulsatile change in temperature between 35 
and 40ºC. [71]US Patents 6733788 and 200200151712 
describe a medical device consisting thermo-sensitive 
cellulose gel structure, through which the bioactive 
solute compound is delivered to a target location in the 
body. [72-73]  
Thermo – responsive polymeric micelle systems 
constitute polymeric micelles whose properties and 
biological interests make them most noteworthy 
candidate as drug carrier for the treatment of cancer. 
[74] The polymeric micelle consists of amphiphilic 
block copolymers exhibiting a hydrophobic core with a 
hydrophilic corona. Due to such properties, these 
polymer micelles exhibit stealth characteristics and are 
not detected by the body defence system. Thus, passive 
targeting could be achieved through enhanced 
permeation retention (EPR) effect of tumoursites. [75] 
Okano and co-workers made the use of an end 
functionalized PIPAAm to prepare block copolymers. 
Hydrophobic Polymers, likepoly (butyl methacrylate) 
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(PBMA), Polystyrene (PSt), [76-77], poly (lactic acid) 
(PLA) [78-79] have been used. 
Electric Field  
An electric field works as an external stimulus with 
several advantages like availability of equipment‘s, 
which allows precise control with regards to the 
magnitude of current, duration of electric pulses, 
interval between pulses etc.  
The mechanism of drug release chiefly includes 
ejection of drug from the gel as the fluid phase 
synereses out, drug diffusion along a concentration 
gradient, the electrophoresis of charged drug towards 
an oppositely charged electrodes and liberation of the 
entrapped drug as the gel complex erodes. [80] 
Pulsatile release systems for vaccine and hormone 
products  
Vaccines are traditionally administered as an initial 
shot of an antigen followed by repeated booster shots 
to produce protective immunity [81]. The frequency of 
the booster shots and therefore the exact immunization 
schedule depends on the antigen. Also, co- 
administration of vaccine adjuvant is given for the 
enhancement of immune response to achieve protective 
immunity. [82] PDDS offers the possibility of single – 
shot vaccines if initial booster release of the antigen 
can be achieved from one system in which timing of 
booster release is controlled.  
Recent techniques of Oral Time Controlled 
Pulsatile Technology  
The current focus of the pharmaceutical companieshas 
been on development and commercialization of PDDS 
that fulfils unmet medical needs in treatment of various 
diseases. Here are few recently developed 
technologies. [10] 
CODAS Technology  
Chronotherapeutic Oral Drug Absorption System 
(COADS) is a multi-particulate system, which is dosed 
at bed time that delays drug release 4-5 hrs. The delay 
is due to the presence of non- enteric coating of the 
drug loaded beads. The technique has been used in 
formulation of Verapamil extended release capsules 
Verelan. [38] 
CEFORM Technology 
This technique helps in the development of 
microspheres of uniform size and shape. It is based on 
―melt spinning‖ in which biodegradable polymer or 
bioactive agent‘s combination is subjected to 
combination of temperature, thermal gradients, flow, 
flow rates during processing. These microspheres can 
be used in tablet, capsule, suspension, sachet form. 
Coating can also be done to get controlled release. [38]  
 PULSYS  
This technology was used to develop 
chromotherapeutic system for amoxicillin. As the 
antibiotics are more effective against fast growing 
bacteria, this system was designed. On the 
administration of immediate release system, bacteria 
respond to it by going into dormant stage, while, in 
pulsatile drug delivery system, pulses are released at 
regular intervals, so bacteria do not get to go into the 
dormant stage effectiveness of this technique has been 
proved. [83] 
 
GEOCLOCK Technology  
Geoclock tablets have an active drug inside an outer 
tablet layer consisting of a mixture of hydrophobic wax 
and brittle material in order to obtain a pH – 
independent lag time prior to core drug delivery at a 
pre- determined release rate. This dry coating approach 
is designed to allow the timed release of both slow 
release and fast release active cores by releasing inner 
core tablet first after which the surrounding outer shell 
gradually disintegrates. This technology has been used 
to develop Lodotra, a rheumatoid arthritis drug, which 
delivers the active pharmaceutical ingredient at most 
suitable time of day to treat the disease condition. [84] 
 
Conclusion  
 
By now, oral delivery of drugs is most pregnable route 
of drug delivery due to the ease of administration, 
patient compliance, and flexibility in its formulations. 
Generally, a sustained and controlled release product 
provide a desired therapeutic effect but fall short of 
diseases following circadian rhythms.  
PDDS can very efficiently tackle the disorders 
following a circadian rhythm as it is modulated 
according to body‘s circadian rhythm giving rise to 
drug release at specified time lag.  
However, for the last two decades, a significant 
progress has been made towards achieving PDDS that 
is capable of treating diseases with non- constant 
dosing therapies. Various pulsatile technologies are on 
their ways and some are currently in the market.  
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